Stockreport

EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

EQRx, Inc.  (EQRX) 
PDF First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated [Read more]